Vivani Medical (VANI) 10-Q 13 Nov 24 2024 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2024	Nov. 12, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2024
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	001-36747
Entity Registrant Name	Vivani Medical, Inc.
Entity Central Index Key	0001266806
Entity Tax Identification Number	02-0692322
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	1350 S. Loop Road
Entity Address, City or Town	Alameda
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94502
City Area Code	(415)
Local Phone Number	506-8462
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	VANI
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		59,234,689

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 19,646	$ 20,654
Prepaid expenses and other current assets	1,753	2,408
Total current assets	21,399	23,062
Property and equipment, net	1,644	1,729
Right-of-use assets	18,383	19,616
Restricted cash	1,338	1,338
Other assets	132	52
Total assets	42,896	45,797
Current liabilities:
Accounts payable	815	542
Accrued expenses	2,024	1,727
Litigation accrual	1,675	1,675
Accrued compensation expense	371	396
Current operating lease liabilities	1,385	1,383
Total current liabilities	6,270	5,723
Long-term operating lease liabilities	18,294	19,313
Total liabilities	24,564	25,036
Stockholders’ equity:
Preferred stock, par value $0.0001 per share; 10,000 shares authorized; none outstanding
Common stock, par value $0.0001 per share; 300,000 shares authorized; shares issued and outstanding: 55,266 and 51,031 at September 30, 2024 and December 31, 2023, respectively	6	5
Additional paid-in capital	134,108	119,054
Accumulated other comprehensive income	92	140
Accumulated deficit	(115,874)	(98,438)
Total stockholders’ equity	18,332	20,761
Total liabilities and stockholders’ equity	$ 42,896	$ 45,797

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	55,266,435	51,031,000
Common stock, shares outstanding	55,266,435	51,031,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Operating expenses:
Research and development, net of grants	$ 4,203	$ 4,441	$ 11,442	$ 12,260
General and administrative, net of grants	2,106	2,703	6,775	8,488
Total operating expenses	6,309	7,144	18,217	20,748
Loss from operations	(6,309)	(7,144)	(18,217)	(20,748)
Other income, net	268	362	781	1,122
Net loss	$ (6,041)	$ (6,782)	$ (17,436)	$ (19,626)
Net loss per common share - basic	$ (0.11)	$ (0.13)	$ (0.32)	$ (0.39)
Net loss per common share - diluted	$ (0.11)	$ (0.13)	$ (0.32)	$ (0.39)
Weighted average common shares outstanding - basic	55,247	50,837	54,161	50,757
Weighted average common shares outstanding - diluted	55,247	50,837	54,161	50,757

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss (unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Statement [Abstract]
Net loss	$ (6,041)	$ (6,782)	$ (17,436)	$ (19,626)
Other comprehensive (loss) income:
Foreign currency translation adjustments	29	(19)	(48)	11
Comprehensive loss	$ (6,012)	$ (6,801)	$ (17,484)	$ (19,615)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (unaudited) - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income [Member]	Accumulated Deficit [Member]
Beginning balance, value at Dec. 31, 2022	$ 44,308	$ 5	$ 117,054	$ 35	$ (72,786)
Beginning balance (in shares) at Dec. 31, 2022		50,736,000
Option exercises
Options exercises (in shares)		53,000
Stock-based compensation expense	369		369
Foreign currency translation adjustments	9			9
Net loss	(6,318)				(6,318)
Ending balance, value at Mar. 31, 2023	38,368	$ 5	117,423	44	(79,104)
Ending balance (in shares) at Mar. 31, 2023		50,789,000
Beginning balance, value at Dec. 31, 2022	44,308	$ 5	117,054	35	(72,786)
Beginning balance (in shares) at Dec. 31, 2022		50,736,000
Net loss	(19,626)
Ending balance, value at Sep. 30, 2023	26,207	$ 5	118,568	46	(92,412)
Ending balance (in shares) at Sep. 30, 2023		51,025
Beginning balance, value at Mar. 31, 2023	38,368	$ 5	117,423	44	(79,104)
Beginning balance (in shares) at Mar. 31, 2023		50,789,000
Option exercises	7		7
Options exercises (in shares)		10,000
Stock-based compensation expense	524		524
Foreign currency translation adjustments	21			21
Net loss	(6,526)				(6,526)
Ending balance, value at Jun. 30, 2023	32,394	$ 5	117,954	65	(85,630)
Ending balance (in shares) at Jun. 30, 2023		50,799,000
Option exercises
Options exercises (in shares)		226,000
Stock-based compensation expense	511		511
Foreign currency translation adjustments	(19)			(19)
Net loss	(6,782)				(6,782)
Ending balance, value at Sep. 30, 2023	26,207	$ 5	118,568	46	(92,412)
Ending balance (in shares) at Sep. 30, 2023		51,025
Beginning balance, value at Dec. 31, 2023	$ 20,761	$ 5	119,054	140	(98,438)
Beginning balance (in shares) at Dec. 31, 2023	51,031,000	51,031,000
Issuance of common stock and warrants in connection with securities purchase agreement, net of issuance costs	$ 13,687		13,687
Issuance of common stock and warrants in connection with securities purchase agreement, net of issuance costs (in shares)		3,947,000
Stock-based compensation expense	353		353
Foreign currency translation adjustments	(52)			(52)
Net loss	(6,039)				(6,039)
Ending balance, value at Mar. 31, 2024	28,710	$ 5	133,094	88	(104,477)
Ending balance (in shares) at Mar. 31, 2024		54,978,000
Beginning balance, value at Dec. 31, 2023	$ 20,761	$ 5	119,054	140	(98,438)
Beginning balance (in shares) at Dec. 31, 2023	51,031,000	51,031,000
Net loss	$ (17,436)
Ending balance, value at Sep. 30, 2024	$ 18,332	$ 6	134,108	92	(115,874)
Ending balance (in shares) at Sep. 30, 2024	55,266,435	55,266,000
Beginning balance, value at Mar. 31, 2024	$ 28,710	$ 5	133,094	88	(104,477)
Beginning balance (in shares) at Mar. 31, 2024		54,978,000
Issuance of common stock in connection with At-the-Market offering, net of issuance costs	112	$ 1	111
Issuance of common stock in connection with At-the-Market offering, net of issuance costs (in shares)		219,000
Stock-based compensation expense	383		383
Foreign currency translation adjustments	(25)			(25)
Net loss	(5,356)				(5,356)
Ending balance, value at Jun. 30, 2024	23,824	$ 6	133,588	63	(109,833)
Ending balance (in shares) at Jun. 30, 2024		55,197,000
Option exercises	103		103
Issuance of common stock and warrants in connection with securities purchase agreement, net of issuance costs
Issuance of common stock in connection with At-the-Market offering, net of issuance costs	48		48
Issuance of common stock in connection with At-the-Market offering, net of issuance costs (in shares)		69,000
Stock-based compensation expense	472		472
Foreign currency translation adjustments	29			29
Net loss	(6,041)				(6,041)
Ending balance, value at Sep. 30, 2024	$ 18,332	$ 6	$ 134,108	$ 92	$ (115,874)
Ending balance (in shares) at Sep. 30, 2024	55,266,435	55,266,000

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Stockholders' Equity (unaudited) (Parentheticals) - Additional Paid-in Capital [Member] - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024
Issuance of common stock and warrants in connection with securities purchase agreement, issuance costs			$ 1,300
Issuance of common stock in connection with At-the-Market offering, issuance costs	$ 43	$ 301

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:
Net loss	$ (17,436)	$ (19,626)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	311	259
Stock-based compensation	1,208	1,404
Non-cash lease expense	216	829
Fixed assets write-off	34
Changes in operating assets and liabilities:
Prepaid expenses and other assets	575	(3,286)
Accounts payable	274	718
Accrued compensation expenses	(25)	18
Accrued expenses	(131)	(534)
Net cash used in operating activities	(14,974)	(20,218)
Cash flows from investing activities:
Purchases of property and equipment	(260)	(144)
Net cash used in investing activities	(260)	(144)
Cash flows from financing activities:
Net proceeds from exercise of options		110
Proceeds from issuance of common stock and warrants in connection with securities purchase agreement, net of issuance costs	13,687
Proceeds from issuance of common stock in connection with the At-the-Market offering, net of issuance costs	160
Net proceeds from insurance premium loan	379
Net cash provided by financing activities	14,226	110
Effect of exchange rate changes on cash and cash equivalents		(3)
Cash, cash equivalents and restricted cash:
Net decrease	(1,008)	(20,255)
Balance at beginning of period	21,992	46,442
Balance at end of period	20,984	26,187
Cash paid during the period for:
Income taxes	2
Non-cash investing and financing activities:
Establishment of operating right-of-use assets through operating lease obligations		$ 20,755

Organization and Business Opera

Organization and Business Operations	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Business Operations	Note 1. Organization and Business Operations Vivani Medical, Inc. (“Vivani,” the “Company,” “we,” “us,” “our” or similar terms) is a preclinical stage biopharmaceutical company which develops miniaturized, subdermal implants utilizing its proprietary NanoPortal™ technology, which is designed to An alarmingly high proportion of patients, approximately 50%, do not take their medicine as prescribed in the real world, a statistic that applies to both daily oral as well as weekly injectable medicines. For example, a recent study has shown that 64% of patients taking Wegovy® (semaglutide injectable) discontinue therapy within the first year of treatment, a number that increases to 76% by the second year. Unfortunately, GLP- 1 At Vivani, we are developing a portfolio of miniature, subdermal six months 1 Vivani resulted from the business combination of Second Sight Medical Products, Inc. (“Second Sight”) and Nano Precision Medical, Inc. (“NPM”). On August 30, 2022, Second Sight and NPM completed their merger pursuant to which NPM became a wholly owned subsidiary of Second Sight and the combined company of NPM and Second Sight was renamed Vivani Medical, Inc. Vivani’s main priority is the further development of its lead program NPM- 115 6 1 one remains In December 2022, we contributed our neurostimulation assets and certain liabilities to Cortigent, Inc. (“Cortigent”), a wholly owned subsidiary of Vivani. Cortigent has 5,000,000 shares of common stock outstanding, all owned by Vivani. Cortigent is advancing the Company’s pioneering neurostimulation technology. In March 2023, Vivani announced the filing of a Registration Statement on Form S- 1 1 On July 6, 2023, Vivani changed its state of incorporation from the State of California to the State of Delaware by means of a plan of conversion, effective July 5, 2023. The reincorporation, including the principal terms of the plan of conversion, was submitted to a vote of, and approved by, Vivani’s stockholders at its 2023 A n Investigational New Drug Application (“IND”) for NPM- 119 1 2 119 119 2 On August 25, 2023, the Company and Cortigent entered into an Amendment 1 1,500,000 five 5 2,000,000 ® In the fourth quarter of 2023 In February 2024, Vivani announced positive preclinical weight loss data with its exenatide implant that was comparable to semaglutide, the active ingredient in Ozempic ® ® ® In February, the Company also disclosed that semaglutide is the active pharmaceutical ingredient in NPM- 139 1 139 On March 1, 2024, the Company entered into a securities purchase agreement (“Securities Purchase Agreement”) with an institutional investor to purchase 3,947,368 shares of common stock, par value $0.0001 per share (the “Common Stock”) and warrants to purchase up to an aggregate of 3,947,368 shares of common stock at a purchase price of $3.80 per share and accompanying warrant in a registered direct offering (the “Offering”). The warrants have an exercise price of $3.80 per share, are exercisable immediately upon issuance, and will expire three years following the date of issuance. On April 22, 2024, the Company entered into an Open Market Sale Agreement SM 3 On May 28, 2024, Vivani announced the publication of positive weight loss data supporting the potential veterinary use of OKV- 119 1 six months 1 As stated previously, on June 13, 2024, Vivani announced that the FDA cleared the IND and lifted the clinical hold for NPM- 119 six 1 2 On July 11, 2024, the Company provided an update of the clinical development plans for NPM- 115 1 1 2 ® ® 1 2024 2025 On September 4, 2024, announced positive preclinical liver fat results with its miniature, ultra long-acting GLP-1 implant currently under development chronic weight management in obese and overweight individuals and type 2 diabetes. The Company's GLP-1 (exenatide) implant produced sham-implant adjusted liver fat reduction of 82% in an obese mouse model from a single administration with expected twice-yearly dosing. These liver fat data are consistent with published results from similar investigations with semaglutide, the active pharmaceutical ingredient in Ozempic ® ® On September 26, 2024, the Company reported receiving regulatory approval to initiate its first in human clinical trial with a miniature, ultra long-acting GLP-1 (exenatide) implant in obese and overweight individuals in Australia. This clinical trial, known as LIBERATE-1™, is part of the NPM-115 program and will investigate the safety, tolerability and full pharmacokinetic profile of an exenatide implant. The trial also represents the first clinical application of the Company’s proprietary NanoPortal™ drug implant technology. LIBERATE-1 is designed to enroll participants who will be titrated on weekly semaglutide injections for 8 weeks 9-week Liquidity and Capital Resources From inception, our operations have been funded primarily through the sales of our common stock and warrants. Our financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. We are subject to the risks and uncertainties associated with a business with no revenue that is developing novel medical devices, including limitations on our operating capital resources. We have incurred recurring operating losses and negative operating cash flows since inception, and we expect to continue to incur operating losses and negative operating cash flows for the foreseeable future. On March 1, 2024, the Company entered into the Securities Purchase Agreement relating to the issuance of 3,947,368 shares of the common stock and warrants to purchase up to an aggregate of 3,947,368 shares of common stock (the “Warrants”), to such investor at a purchase price of $3.80 per share and accompanying warrants in the Offering. The Warrants have an exercise price of $3.80 per share, are exercisable immediately upon issuance and will expire three years 15.0 $1.3 million, resulting in net proceeds of $13.7 million 7 On April 22, 2024, the Company entered into the Sales Agreement with Jefferies, under which the Company may offer and sell, from time to time at its sole discretion, shares of the common stock, having an aggregate offering price of up to $75.0 million through Jefferies as its sales agent. Also on April 22, 2024, the Company filed a Registration Statement on Form S- 3 7 We estimate that currently available cash will provide sufficient funds to enable the Company to meet its planned obligations for at least the next twelve months

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	Note 2. Basis of Presentation and Significant Accounting Policies Basis of Presentation These unaudited interim financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) and following the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP can be condensed or omitted. In our opinion, the unaudited interim financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of our financial position and our results of operations and cash flows for periods presented. These statements do not include all disclosures required by GAAP and should be read in conjunction with our financial statements and accompanying notes for the fiscal year ended December 31, 2023 Principles of Consolidation The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. Intercompany balances and transactions have been eliminated in consolidation. Use of estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting Operating Segments Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. Our chief operating decision-maker, our Chief Executive Officer, reviews financial information presented for each of our segments. We have two During the three months ended September 30, 2024 Division and Division incurred operating expenses of $ million and $ million, respectively. During the three months ended September 30, 2024 Division was $ million and for the Division was $ million. During the nine months ended September 30, 2024 16.6 million 1.6 million September 30, 2024 15.7 million 1.7 million As of September 30, 2024 The Company’s long-term assets are located in the United States. Significant Accounting Policies Our significant accounting policies are set forth in our financial statements for the year ended December 31, 2023 December 31, 2023 Recently Issued Accounting Pronouncements In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023 07 Improvements to Reportable Segment Disclosures (Topic 280 In December 2023, the FASB issued ASU No. 2023 09 Improvements to Income Tax Disclosures (Topic 740

Concentration of Risk

Concentration of Risk	9 Months Ended
	Sep. 30, 2024
Cash and Cash Equivalents [Abstract]
Concentration of Risk	Note 3. Concentration of Risk Credit Risk Financial instruments that subject us to concentrations of credit risk consist primarily of cash, certificates of deposit and money market funds. We maintain cash, certificates of deposit and money market funds with financial institutions that we deem reputable. Foreign Operations The accompanying condensed consolidated financial statements as of September 30, 2024 2023 $ 27,000 0.1

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 4. Fair Value Measurements The authoritative guidance with respect to fair value establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair value measurements, is also required. Level 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that we have the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives. Level 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange-based derivatives, mutual funds, and fair-value hedges. Level 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently traded non-exchange-based derivatives and commingled investment funds, and are measured using present value pricing models. We determine the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, we perform an analysis of the assets and liabilities at each reporting period end. Cash equivalents, which include certificates of deposit and money market funds, are the only financial instruments measured and recorded at fair value on our condensed consolidated balance sheet, and are valued using Level 1 inputs. As of September 30, 2024 2023 September 30, 2024 2023 The following table summarizes assets measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): As of September 30, 2024 Total Level 1 Level 2 Level 3 Assets Cash equivalents: Certificates of deposit $ 7,112 $ 7,112 $ - $ - Money market funds 11,112 11,112 - - Total $ 18,224 $ 18,224 $ - $ - As of December 31, 2023 Total Level 1 Level 2 Level 3 Assets Cash equivalents: Money market funds $ 18,629 $ 18,629 $ - $ - Total $ 18,629 $ 18,629 $ - $ -

Insurance Premium Financing

Insurance Premium Financing	9 Months Ended
	Sep. 30, 2024
Debt Disclosure [Abstract]
Insurance Premium Financing	Note 5 Insurance Premium Financing In September 2024, we entered into a finance agreement with First Insurance Funding in order to fund a portion of our insurance premiums for our professional liability policies. The amount financed is approximately $ 426,000 and incurs interest at a rate of 7.2 % . The Company is required to make nine monthly payments of approximately $ 47,000 through May 2025 . The outstanding balance as of September 30, 2024 was approximately $ 379,000 and is included in accrued expenses in the accompanying condensed consolidated balance sheet .

Selected Balance Sheet Detail

Selected Balance Sheet Detail	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Selected Balance Sheet Detail	Note 6. Selected Balance Sheet Detail Property and Equipment, Net Property and equipment, net consisted of the following (in thousands): September 30, December 31, 2024 2023 Property and equipment at cost: Equipment $ 3,789 $ 3,511 Furniture and fixtures 367 354 Computer software 30 7 Construction in progress - 299 Total property and equipment 4,186 4,171 Accumulated depreciation and amortization (2,542 ) (2,442 ) Property and equipment, net $ 1,644 $ 1,729

Equity Securities

Equity Securities	9 Months Ended
	Sep. 30, 2024
Equity [Abstract]
Equity Securities	Note 7. Equity Securities We are authorized to issue 300,000,000 55,266,435 September 30, 2024 10,000,000 none September 30, 2024 Securities Purchase Agreement On March 1, 2024, the Company entered into the Securities Purchase Agreement relating to the issuance of 3,947,368 shares of the common stock and Warrants to purchase up to an aggregate of 3,947,368 shares of common stock, at a purchase price of $3.80 per share and accompanying warrants in the Offering. The Warrants have an exercise price of $3.80 per share, are exercisable immediately upon issuance and will expire three years following the date of issuance. The Company also entered into a Placement Agency Agreement with Maxim, who acted as the sole placement agent for the Offering. In connection with the Placement Agency Agreement, the Company agreed to pay Maxim an aggregate cash fee of 7.0% of the aggregate proceeds raised from the sale and issuance of the shares of common stock and accompanying warrants. Pursuant to the Placement Agency Agreement, the Company also agreed to reimburse Maxim up to $65,000 for its legal expenses. 15.0 1.3 million 13.7 million Pursuant to the terms of the Securities Purchase Agreement, until 45 days following the closing of the Offering, the Company agreed not to issue (or enter into any agreement to issue) any shares of common stock or common stock equivalents, subject to certain exceptions. The Company has further agreed not to enter into an agreement involving a variable rate transaction until one year following the closing of the Offering. In addition, the Company’s directors and officers have entered into lock-up agreements with the Company pursuant to which each of them has agreed not to, for a period of 90 days from the closing of the Offering, offer, sell, transfer or otherwise dispose of the Company’s securities, subject to certain exceptions. At-the-Market Sales Agreement On April 22, 2024, the Company entered into the Sales Agreement with Jefferies, under which the Company may offer and sell, from time to time at its sole discretion, shares of the common stock, having an aggregate offering price of up to $75.0 million through Jefferies as its sales agent. Also on April 22, 2024, the Company filed a Registration Statement on Form S- 3 The Company may sell the common stock under the Sales Agreement (A) in privately negotiated transactions; (B) as block transactions; or (C) by any other method permitted by law deemed to be an “at-the-market” offering as defined in Rule 415 4 1933 three The Company is not obligated to make any sales of common stock under the Sales Agreement. The offering of shares of common stock pursuant to the Sales Agreement will terminate upon the earlier of (i) the sale of all common stock subject to the Sales Agreement or (ii) termination of the Sales Agreement in accordance with its terms. During the nine months ended September

Warrants

Warrants	9 Months Ended
	Sep. 30, 2024
Warrants
Warrants	Note 8. Warrants A summary of warrant activity for the nine months ended September 30, 2024 Number of Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Life (in Years) Warrants outstanding as of December 31, 2023 9,733 $ 11.60 1.4 Issued 3,947 $ 3.80 Exercised - $ - Forfeited or expired (3,768 ) $ 24.98 Warrants outstanding as of September 30, 2024 9,912 $ 3.41 2.28 Warrants exercisable as of September 30, 2024 9,912 $ 3.41 2.28 NPM, prior to the merger with Second Sight, issued common stock and warrants (collectively, the “unit” or “units”) in 2019 2020 2021 3.15 3.15 one Second Sight underwriter warrants of 10,125 3,375 3.75 In connection with the Securities Purchase Agreement entered on March 1, 2024, relating to the issuance of 3,947,368 shares of the common stock, par value of $0.0001 per share, the Company issued Warrants to purchase 3,947,368 shares of common stock at an exercise price of $3.80 per share. These Warrants are exercisable immediately upon issuance and will expire three years following the date of issuance. The warrants outstanding as of September 30, 2024

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2024
Stock-Based Compensation
Stock-Based Compensation	Note 9. Stock-Based Compensation Equity Incentive Plan The Vivani Medical, Inc. 2022 2022 Under the 2022 Plan, 10,033,333 shares were authorized for issuance at its effective date. The maximum number of shares with respect to which stock awards could be granted is offset and reduced by stock awards previously granted under the 2022 Plan September 30, 2024 2,165,958 2022 For stock option grants, the option price is determined by the Board of Directors but cannot be less than the fair value of the shares at the grant date. Generally, the options vest ratably over four years and expire ten years from the grant date. Stock Options A summary of stock option activity is presented below (in thousands, except per share and contractual life data). Weighted Weighted Average Average Remaining Exercise Contractual Number of Price Life Shares Per Share (in Years) Options outstanding as of December 31, 2023 6,091 $ 2.60 6.96 Granted 1,093 $ 1.57 Exercised - $ - Forfeited or expired (375 ) $ 1.19 Options outstanding, vested and expected to vest as of September 30, 2024 6,809 $ 2.52 6.80 Options exercisable as of September 30, 2024 4,660 $ 2.94 5.87 The estimated aggregate intrinsic value of stock options exercisable as of September 30, 2024 0.01 million Restricted Stock Units (RSUs) A summary of restricted stock activity and related information (in thousands, except per share data): Number of Shares Weighted Average Grant Date Fair Value Per Share Outstanding as of December 31, 2023 403 $ 0.93 Granted 292 $ 1.69 Vested and released - $ - Forfeited and canceled - $ - Outstanding as of September 30, 2024 695 $ 1.25 During the nine months ended September 30, 2024 granted 292,500 3.15 four years one one During the nine months ended September 30, 2023 granted 402,500 one one Stock-Based Compensation Expense The following table summarizes total stock-based compensation expense for stock options and RSUs, which is included in the statements of operations (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Research and development $ 275 $ 277 $ 757 $ 809 General and administrative 197 234 451 595 Total stock-based compensation expense $ 472 $ 511 $ 1,208 $ 1,404 As of September 30, 2024 2.2 1.4 September 30, 2024 $0.3 million of total unrecognized compensation expense related to outstanding RSUs over a weighted average period of 0.8 year. Stock During the nine months ended September 30, 2024 1,092,836 ten years 1.57 four years Stock Options (Service Vesting) During the nine months ended September 30, 2024 1,092,836 1.4 million nine months ended September 30, 2023 1.1 million Summary of Option Grant using the Black-Scholes Option-pricing Model Nine Months Ended September 30, 2024 2023 Risk-free interest rate 3.79 5.53 3.99 4.45 Expected dividend yield - - Expected volatility 100 100 Expected term 5.04 6.08 4.00 6.20 Stock Options (Market Conditions Vesting) During the nine months ended September 30, 2023 200,000 3.15 three four years These stock options with market conditions vesting were valued at $0.1 million. three months ended September 30, 2024 2023 nine months ended September 30, 2024 2023 ● Beginning Stock Price. ● Drift Rate. two years ● Volatility. ● Period. ● Dividends. Restricted Stock Units (RSUs) During the nine months ended September 30, 2024 292,500 These RSUs are subject to performance vesting criteria, based on market conditions which required our stock price to exceed $3.15 per share for three consecutive days in the four years from grant date for the RSUs to vest. The Company recognized the associated stock-based compensation expense of $126,000 and $0 during the three months ended September 30, 2024 2023 nine months ended September 30, 2024 nine months ended September 30, 2024 September 30, 2023 Nine Months Ended September 30, Nine Months Ended September 30, 2024 2023 RSUs Granted 292,500 402,500 Valuation date stock price $1.81 $0.93 Risk-free interest rate 4.53% 4.13% Expected dividend 0% 0% Expected volatility 100% 100% Simulation term 4 Years 1.1 Years The steps involved in utilizing the Monte Carlo simulation in order to value the performance-based RSUs included the following: 1 four years Additionally, we considered the two six 252 ● Beginning Stock Price. ● Drift Rate. two years ● Volatility. ● Period. ● Dividends. 2 1 3 1 3 one 1 3 two 3

Net Loss Per Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2024
Earnings Per Share [Abstract]
Net Loss Per Share	Note 10. Net Loss Per Share Basic net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during the period, without consideration of potential dilutive securities. Diluted net loss per share is computed by dividing the net loss by the sum of the weighted average number of shares of common stock outstanding during the period plus the dilutive effects of potentially dilutive securities outstanding during the period. Potentially dilutive securities include common stock options, RSUs and warrants issued and outstanding. The following table sets forth the computation of basic and diluted net loss per share (in thousands, except per share amounts): Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Numerator: Net loss $ (6,041 ) $ (6,782 ) $ (17,436 ) $ (19,626 ) Denominator: Weighted average common shares outstanding - basic and diluted 55,247 50,837 54,161 50,757 Net loss per common share, basic and diluted $ (0.11 ) $ (0.13 ) $ (0.32 ) $ (0.39 ) Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share for all periods presented, as the inclusion of all potential common stock equivalents outstanding would have been antidilutive. During the periods ended September 30, 2024 2023 September 2024 2023 Stock options issued and outstanding 6,809 6,043 Unvested restricted stock units issued and outstanding 695 403 Warrants to purchase common stock 9,912 10,311 Total 17,416 16,757

Right-of-use Assets and Operati

Right-of-use Assets and Operating Lease Liabilities	9 Months Ended
	Sep. 30, 2024
Right-of-use Assets And Operating Lease Liabilities
Right-of-use Assets and Operating Lease Liabilities	Note 11. Right-of-use Assets and Operating Lease Liabilities We lease certain office, laboratory, research and development space for our use. Leases with an initial term of 12 months or less are not recorded on the balance sheet. Lease costs are recognized in the income statement over the lease term on a straight-line basis. Depreciation is computed using the straight-line method over the estimated useful life of the respective assets. The depreciable life of assets and leasehold improvements are limited by the expected lease term. Our lease agreements do not contain any material residual value guarantees or restrictive covenants. As most of our leases do not provide an implicit rate, we used our estimated incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. On November 21, 2022, Vivani entered into a triple net lease agreement for a single building with 43,645 square feet of space in Alameda, California. The stated term of the lease commenced on June 1, 2023 and terminates on September 30, 2033, ten years and four months. The lease term is based on the non-cancellable period in the lease agreement. There are two options to extend the lease, each for a term of five years; however, the extension options were not included in the measurement of the ROU asset and lease liability since it is not reasonably certain that the Company will exercise such extension options. Payments increase annually from $2,676,311 to $3,596,784, or 124 monthly payments less the first four which are abated, totaling approximately $31.0 million. Vivani is responsible for insurance, property taxes and common area maintenance charges. Vivani deposited $1.3 million to guarantee a letter of credit to secure the lease and this amount is recorded as restricted cash, long-term on the balance sheets as of September 30, 2024 and December 31, 2023. On February 1, 2023, we entered into a lease agreement, effective March 1, 2023 22,158 lease 14,823 square feet of office space at 27200 Tourney Road, Valencia, California 91355. The sublease has a term of two years and two months. We also entered into a lease for storage space on January 25, 2023, in the same building at a cost of $6,775 per month for a term of two years and one month. The following table summarizes supplemental balance sheet information related to the Company’s operating leases (in thousands): September 30, December 31, Balance Sheet Classification 2024 2023 Assets Non-current assets Right-of-use assets $ 18,383 $ 19,616 Liabilities Current Current operating lease liabilities $ 1,385 $ 1,383 Long-term Long-term operating lease liabilities $ 18,294 $ 19,313 Operating lease cost was $ 0.8 1.1 three months ended September 30, 2024 2023 nine months ended September 30, 2024 2023 Variable lease cost, comprising primarily of common area maintenance charges and taxes, for the operating lease was $ 0.1 0.4 three months ended September 30, 2024 2023 nine months ended September 30, 2024 2023 The following table summarizes a maturity analysis of our lease liabilities showing the aggregate lease payments as of September 30, 2024 Year Ending December 31, Amount 2024 $ 775 2025 2,914 2026 2,889 2027 2,976 2028 3,065 Thereafter 15,862 Total lease payments $ 28,481 Less imputed interest (8,802 ) Total lease liabilities $ 19,679 Weighted average discount rate 8.40 % Weighted average remaining lease term 8.90 years Other information related to leases are as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Cash paid for operating lease liabilities $ 776 $ 375 $ 2,294 $ 1,134

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2024
Commitments and Contingencies [Abstract]
Commitments and Contingencies	Note 12. Commitments and Contingencies Indemnification Agreements We maintain indemnification agreements with our directors and officers that may require us to indemnify them against liabilities that arise by reason of their status or service as directors or officers, except as prohibited by applicable law. Clinical Trial Agreements Based upon FDA approval of Argus II, which was obtained in February 2013, we were required to collect follow-up data from subjects enrolled in our pre-approval trial for a period of up to ten years post-implant, which was extended through the year 2019. This requirement to collect follow-up data was halted in 2020 with FDA approval. In addition, we conducted three post-market studies to comply with U.S. FDA, French, and European post-market surveillance regulations and requirements and are conducting an early feasibility clinical study of Orion. We have contracted with various universities, hospitals, and medical practices to provide these services. Payments are based on procedures performed for each subject and are charged to clinical and regulatory expense as incurred. Total amounts expensed during the three months ended September 30, 2024 2023 3,000 4,000 nine months ended September 30, 2024 Litigation, Claims and Assessments One opposition filed by Pixium Vision SA (“Pixium”) is pending in the European Patent Office challenging the validity of a European patent owned by Cortigent. The outcome of the challenge is not certain, however, if successful, it may affect our ability to block competitors from utilizing Cortigent’s neurostimulation patented technology. We believe a successful challenge will not have a material effect on our ability to manufacture and sell our products, or otherwise have a material effect on Cortigent’s operations. As described in the Company’s 10-K for the year ended December 31, 2020, the Company had entered into a Memorandum of Understanding (“MOU”) for a proposed business combination with Pixium. In response to a press release by Pixium dated March 24, 2021, and subsequent communications between us and Pixium, our Board of Directors determined that the business combination with Pixium was not in the best interest of our shareholders. On April 1, 2021, we gave notice to Pixium that we were terminating the MOU between the parties and seeking an amicable resolution of termination amounts that may be due, however no assurance can be given that an amicable resolution will be reached. We accrued $1,000,000 of liquidated damages as contemplated by the MOU in accounts payable as of March 31, 2021 and remitted that amount to Pixium in April 2021. Pixium indicated that it considered this termination wrongful, rejected the Company’s offers, but retained the $1,000,000 payment. On May 19, 2021, Pixium filed suit in the Paris Commercial Court, and currently claim damages of approximately €5.1 million or about $5.6 million. We believe we have fulfilled our obligations to Pixium with the liquidated damages payment of $1,000,000. On December 8, 2022, the Company received notice that the Paris Commercial Court has rendered its judgment, including finding that the Company’s termination of the MOU was not valid. In the judgment, the Company was ordered to pay to Pixium the amount of €2,500,000 minus a €947,780 credit for the $1,000,000 already paid for, a net amount payable of approximately €1,552,220. On May 24, 2023, the Company filed an appeal against the judgment from the Paris Commercial Court except in so far as such prior judgment dismissed (i) Pixium’s claim for the Company to pay it a sum of €480,693 relating to the alleged time spent by its teams, (ii) Pixium’s application to order the Company to pay it a sum of €1,500,000 in respect to alleged loss of opportunity and (iii) deducted the sum of $1,000,000 that we already paid Pixium and which Pixium retained converted into euros at the date of the judgment. Thereafter Pixium filed its brief with Paris Court of Appeal and filed a cross-appeal on January 18, 2024. Meanwhile, the Company received notice that the Paris Commercial Court had opened safeguard proceedings against Pixium by judgment dated October 9, 2023, then in its judgment dated November 13, 2023, converted safeguard proceedings into receivership, and in its judgment dated January 31, 2024, converted Pixium’s receivership proceedings to liquidation proceedings, the transfer plan being rejected. As a result, Pixium’s liquidator intervened on behalf of Pixium in the pending proceedings before the Paris Court of Appeal and filed its brief on March 21, 2024. The Company filed its brief in reply with the Paris Court of Appeal on April 17, 2024. Proceedings before the Paris Court of Appeal are pending. In parallel, since the Company has failed to enforce the judgment, Pixium has requested the pre-trial judge to strike out the Company's appeal for failure to enforce the judgment. The hearing took place on June 4, 2024 and on October 23, 2024, the pre-trial judge issued his order, striking out Vivani's appeal for failure to enforce the decision. Within two years, Vivani will have to request that the case be reinstated on the court's docket, providing evidence that the judgment has been fully enforced or, at the very least, that an agreement has been reached. Failing this, the appeal proceedings will lapse. The Company recorded a charge of $1,675,000 for the year ended December 31, 2022, related to this matter but plans to continue its appeal against the preliminary judgment. We are party to litigation arising in the ordinary course of business. It is our opinion that the outcome of such matters will not have a material effect on our results of operations, however, the results of litigation and claims are inherently unpredictable. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2024
Subsequent Events
Subsequent Event	Note 13. Subsequent Event On November 8, 2024, the Company entered into a private sale transaction with one

Insider Trading Arrangements

Insider Trading Arrangements	9 Months Ended
	Sep. 30, 2024 shares
Trading Arrangements, by Individual [Table]
Trading Arrangement, Securities Aggregate Available Amount	3,968,253
Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false
Material Terms of Trading Arrangement [Text Block]	(a) Private Sale Transaction The information set forth below is included for the purpose of providing disclosure under “Item 1.01 - Entry into a Material Definitive Agreement,” and “Item 3.02 – Unregistered Sales of Equity Securities” of Form 8-K. On November 8, 2024, the Company entered into a private sale transaction with one of its independent directors whereby the Company sold an aggregate of 3,968,253 shares of the Company’s common stock to the director at a price of $1.26 per share, which was the lower of the closing price of the Company’s common stock on the Nasdaq or the 5-day average closing price of the Company’s common stock on the Nasdaq, each immediately prior to the closing date, subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the common stock that occur after the date of the private sale transaction. The gross proceeds from this private sale transaction were $5,000,000.00. (c) Rule 10b5-1 Trading Plan Disclosure No Rule 10b5-1 plans non-Rule 10b5-1 trading arrangements adopted terminated September 30, 2024

Basis of Presentation and Sig_2

Basis of Presentation and Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation These unaudited interim financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) and following the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP can be condensed or omitted. In our opinion, the unaudited interim financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of our financial position and our results of operations and cash flows for periods presented. These statements do not include all disclosures required by GAAP and should be read in conjunction with our financial statements and accompanying notes for the fiscal year ended December 31, 2023
Principles of Consolidation	Principles of Consolidation The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. Intercompany balances and transactions have been eliminated in consolidation.
Use of estimates	Use of estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting
Operating Segments	Operating Segments Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. Our chief operating decision-maker, our Chief Executive Officer, reviews financial information presented for each of our segments. We have two During the three months ended September 30, 2024 Division and Division incurred operating expenses of $ million and $ million, respectively. During the three months ended September 30, 2024 Division was $ million and for the Division was $ million. During the nine months ended September 30, 2024 16.6 million 1.6 million September 30, 2024 15.7 million 1.7 million As of September 30, 2024 The Company’s long-term assets are located in the United States.
Significant Accounting Policies	Significant Accounting Policies Our significant accounting policies are set forth in our financial statements for the year ended December 31, 2023 December 31, 2023
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023 07 Improvements to Reportable Segment Disclosures (Topic 280 In December 2023, the FASB issued ASU No. 2023 09 Improvements to Income Tax Disclosures (Topic 740

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2024
Fair Value Disclosures [Abstract]
The following table summarizes assets measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):	The following table summarizes assets measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): As of September 30, 2024 Total Level 1 Level 2 Level 3 Assets Cash equivalents: Certificates of deposit $ 7,112 $ 7,112 $ - $ - Money market funds 11,112 11,112 - - Total $ 18,224 $ 18,224 $ - $ - As of December 31, 2023 Total Level 1 Level 2 Level 3 Assets Cash equivalents: Money market funds $ 18,629 $ 18,629 $ - $ - Total $ 18,629 $ 18,629 $ - $ -

Selected Balance Sheet Detail (

Selected Balance Sheet Detail (Tables)	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Property and equipment, net consisted of the following (in thousands):	Property and equipment, net consisted of the following (in thousands): September 30, December 31, 2024 2023 Property and equipment at cost: Equipment $ 3,789 $ 3,511 Furniture and fixtures 367 354 Computer software 30 7 Construction in progress - 299 Total property and equipment 4,186 4,171 Accumulated depreciation and amortization (2,542 ) (2,442 ) Property and equipment, net $ 1,644 $ 1,729

Warrants (Tables)

Warrants (Tables)	9 Months Ended
	Sep. 30, 2024
Warrants
A summary of warrant activity for the six months ended June 30, 2024 is presented below (in thousands, except per share and contractual life data).	A summary of warrant activity for the nine months ended September 30, 2024 Number of Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Life (in Years) Warrants outstanding as of December 31, 2023 9,733 $ 11.60 1.4 Issued 3,947 $ 3.80 Exercised - $ - Forfeited or expired (3,768 ) $ 24.98 Warrants outstanding as of September 30, 2024 9,912 $ 3.41 2.28 Warrants exercisable as of September 30, 2024 9,912 $ 3.41 2.28

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2024
Stock-Based Compensation
A summary of stock option activity is presented below (in thousands, except per share and contractual life data).	A summary of stock option activity is presented below (in thousands, except per share and contractual life data). Weighted Weighted Average Average Remaining Exercise Contractual Number of Price Life Shares Per Share (in Years) Options outstanding as of December 31, 2023 6,091 $ 2.60 6.96 Granted 1,093 $ 1.57 Exercised - $ - Forfeited or expired (375 ) $ 1.19 Options outstanding, vested and expected to vest as of September 30, 2024 6,809 $ 2.52 6.80 Options exercisable as of September 30, 2024 4,660 $ 2.94 5.87
A summary of restricted stock activity and related information (in thousands, except per share data):	A summary of restricted stock activity and related information (in thousands, except per share data): Number of Shares Weighted Average Grant Date Fair Value Per Share Outstanding as of December 31, 2023 403 $ 0.93 Granted 292 $ 1.69 Vested and released - $ - Forfeited and canceled - $ - Outstanding as of September 30, 2024 695 $ 1.25
The following table summarizes total stock-based compensation expense for stock options and RSUs, which is included in the statements of operations (in thousands):	The following table summarizes total stock-based compensation expense for stock options and RSUs, which is included in the statements of operations (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Research and development $ 275 $ 277 $ 757 $ 809 General and administrative 197 234 451 595 Total stock-based compensation expense $ 472 $ 511 $ 1,208 $ 1,404
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Summary of Option Grant using the Black-Scholes Option-pricing Model Nine Months Ended September 30, 2024 2023 Risk-free interest rate 3.79 5.53 3.99 4.45 Expected dividend yield - - Expected volatility 100 100 Expected term 5.04 6.08 4.00 6.20
Schedule of Share-Based Payment Award, Restricted Stock Units, Valuation Assumptions [Table Text Block]	Nine Months Ended September 30, Nine Months Ended September 30, 2024 2023 RSUs Granted 292,500 402,500 Valuation date stock price $1.81 $0.93 Risk-free interest rate 4.53% 4.13% Expected dividend 0% 0% Expected volatility 100% 100% Simulation term 4 Years 1.1 Years

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2024
Earnings Per Share [Abstract]
The following table sets forth the computation of basic and diluted net loss per share (in thousands, except per share amounts):	The following table sets forth the computation of basic and diluted net loss per share (in thousands, except per share amounts): Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Numerator: Net loss $ (6,041 ) $ (6,782 ) $ (17,436 ) $ (19,626 ) Denominator: Weighted average common shares outstanding - basic and diluted 55,247 50,837 54,161 50,757 Net loss per common share, basic and diluted $ (0.11 ) $ (0.13 ) $ (0.32 ) $ (0.39 )
During the six months ended June 30, 2024 and 2023, the following common stock equivalents were excluded from the computation of diluted net loss per share because including them would have been antidilutive (in thousands).	During the periods ended September 30, 2024 2023 September 2024 2023 Stock options issued and outstanding 6,809 6,043 Unvested restricted stock units issued and outstanding 695 403 Warrants to purchase common stock 9,912 10,311 Total 17,416 16,757

Right-of-use Assets and Opera_2

Right-of-use Assets and Operating Lease Liabilities (Tables)	9 Months Ended
	Sep. 30, 2024
Right-of-use Assets And Operating Lease Liabilities
The following table summarizes supplemental balance sheet information related to the Company’s operating leases (in thousands):	The following table summarizes supplemental balance sheet information related to the Company’s operating leases (in thousands): September 30, December 31, Balance Sheet Classification 2024 2023 Assets Non-current assets Right-of-use assets $ 18,383 $ 19,616 Liabilities Current Current operating lease liabilities $ 1,385 $ 1,383 Long-term Long-term operating lease liabilities $ 18,294 $ 19,313
The following table summarizes a maturity analysis of our lease liabilities showing the aggregate lease payments as of March 31, 2024 (in thousands except weighted average data):	The following table summarizes a maturity analysis of our lease liabilities showing the aggregate lease payments as of September 30, 2024 Year Ending December 31, Amount 2024 $ 775 2025 2,914 2026 2,889 2027 2,976 2028 3,065 Thereafter 15,862 Total lease payments $ 28,481 Less imputed interest (8,802 ) Total lease liabilities $ 19,679 Weighted average discount rate 8.40 % Weighted average remaining lease term 8.90 years
Other information related to leases are as follows (in thousands):	Other information related to leases are as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Cash paid for operating lease liabilities $ 776 $ 375 $ 2,294 $ 1,134

Organization and Business Ope_2

Organization and Business Operations (Details Narrative)

1 Months Ended

3 Months Ended

9 Months Ended

Sep. 26, 2024 wk

Sep. 04, 2024

Jul. 11, 2024 wk

May 28, 2024

Mar. 05, 2024 USD ($)

Mar. 01, 2024 USD ($) $ / shares shares

Aug. 25, 2023 USD ($)

Feb. 29, 2024

Oct. 31, 2023 Employee

Mar. 31, 2024 shares

Sep. 30, 2024 USD ($) $ / shares shares

Sep. 30, 2023 USD ($) shares

Jun. 30, 2024 shares

Apr. 22, 2024 USD ($)

Dec. 31, 2023 $ / shares shares

Jul. 06, 2023 $ / shares

Jun. 30, 2023 shares

Mar. 31, 2023 shares

Dec. 31, 2022 shares

Organization and Business Operations

Percentage of patients do not take their medicine as prescribed in real world

50%

Percentage of patients taking Wegovy (semaglutide injectable) discontinue therapy within first year of treatment

64%

Percentage of patients taking Wegovy (semaglutide injectable) discontinue therapy within second year of treatment

76%

Common stock, shares outstanding | shares

55,266,435

51,031,000

Common stock, par value (in dollars per share) | $ / shares

$ 0.0001

Percentage of weight loss after exenatide implant therapy for patients whom has high-fat diet-induced obese mice

20%

Period of sham implant control therapy

28 days

Period of specific therapy with a single administration

6 months

Percentage of liver fat reduction after exenatide implant therapy for patients whom has high-fat diet-induced obese mice

82%

Number of weeks before being randomized to receive a therapy | wk

8

8

Number of weeks for weekly semaglutide injections therapy | wk

9

9

Revenue from contract with customer

$ 0

Proceeds from issuance of common stock and warrants in connection with securities purchase agreement, net of issuance costs

$ 13,687,000

Minimum [Member]

Organization and Business Operations

Period for delivering therapeutic drug levels

6 months

Warrant [Member]

Organization and Business Operations

Exercise price per share | $ / shares

$ 3.41

$ 11.6

Common Stock [Member]

Organization and Business Operations

Common stock, shares outstanding | shares

54,978,000

55,266,000

51,025

55,197,000

51,031,000

50,799,000

50,789,000

50,736,000

Issuance of common stock and warrants in connection with securities purchase agreement, net of issuance costs (in shares) | shares

3,947,000

Securities Purchase Agreement [Member]

Organization and Business Operations

Gross proceeds

$ 15,000,000

$ 15,000,000

Stock issuance costs

$ 1,300,000

Proceeds from issuance of common stock and warrants in connection with securities purchase agreement, net of issuance costs

13,700,000

Securities Purchase Agreement [Member] | Warrant [Member]

Organization and Business Operations

Exercise price per share | $ / shares

$ 3.8

Warrant term

3 years

Securities Purchase Agreement [Member] | Common Stock [Member]

Organization and Business Operations

Common stock, par value (in dollars per share) | $ / shares

$ 0.0001

Issuance of common stock and warrants in connection with securities purchase agreement, net of issuance costs (in shares) | shares

3,947,368

Securities Purchase Agreement [Member] | Common Stock [Member] | Warrant [Member]

Organization and Business Operations

Number of securities called by warrants | shares

3,947,368

Share price (in dollars per share) | $ / shares

$ 3.8

Sales Agreement [Member]

Organization and Business Operations

Stock issuance costs

$ 344,000

Sales Agreement [Member] | Jefferies LLC (“Jefferies”) [Member]

Organization and Business Operations

Aggregate offering price

$ 75,000,000

Cortigent, Inc. [Member]

Organization and Business Operations

Common stock, shares outstanding | shares

5,000,000

Amount agreed to pay by related party

$ 1,500,000

Number of employees before implemented a reduction-in-force to conserve cash | Employee

14

Number of employees after implemented a reduction-in-force to conserve cash | Employee

7

Cortigent, Inc. [Member] | Promissory note [Member]

Organization and Business Operations

Debt instrument, term

5 years

Debt instrument, interest rate, stated percentage

5%

Debt instrument, face amount

$ 2,000,000

Basis of Presentation and Sig_3

Basis of Presentation and Significant Accounting Policies (Details Narrative) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2024 USD ($)	Jun. 30, 2024 USD ($)	Mar. 31, 2024 USD ($)	Sep. 30, 2023 USD ($)	Jun. 30, 2023 USD ($)	Mar. 31, 2023 USD ($)	Sep. 30, 2024 USD ($) Segment	Sep. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)
Number of operating segments | Segment							2
Operating expenses	$ 6,309			$ 7,144			$ 18,217	$ 20,748
Net Income (Loss) Attributable to Parent	(6,041)	$ (5,356)	$ (6,039)	$ (6,782)	$ (6,526)	$ (6,318)	(17,436)	$ (19,626)
Total Assets	42,896						42,896		$ 45,797
Biopharm Division [Member]
Operating expenses	5,700						16,600
Net Income (Loss) Attributable to Parent	5,400						15,700
Total Assets	41,600						41,600
Neuromodulation Division [Member]
Operating expenses	600						1,600
Net Income (Loss) Attributable to Parent	600						1,700
Total Assets	$ 1,300						$ 1,300

Concentration of Risk (Details

Concentration of Risk (Details Narrative) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Assets amount	$ 42,896,000	$ 45,797,000
Eyes Second Sight Switzerland Sarl [Member]
Assets amount	$ 27,000	$ 100,000

The following table summarizes

The following table summarizes assets measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds	$ 18,224	$ 18,629
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds	18,224	18,629
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds
Certificates of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds	7,112
Certificates of Deposit [Member] | Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds	7,112
Certificates of Deposit [Member] | Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds
Certificates of Deposit [Member] | Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds
Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds	11,112	18,629
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds	11,112	18,629
Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds
Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds

Insurance Premium Financing (De

Insurance Premium Financing (Details Narrative) - Loans Payable [Member] $ in Thousands	1 Months Ended
	Sep. 30, 2024 USD ($) Number
Short-Term Debt [Line Items]
Debt instrument, principal amount	$ 426,000
Debt instrument, interest rate	7.20%
Number of periodic payments | Number	9
Debt Instrument, Frequency of Periodic Payment	monthly
Debt Instrument, Periodic Payment	$ 47,000
Debt instrument, outstanding amount	$ 379,000

Selected Balance Sheet Detail_2

Selected Balance Sheet Detail (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 4,186	$ 4,171
Accumulated depreciation and amortization	(2,542)	(2,442)
Property and equipment, net	1,644	1,729
Equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	3,789	3,511
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	367	354
Computer Software [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	30	7
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment		$ 299

Equity Securities (Details Narr

Equity Securities (Details Narrative) - USD ($)				3 Months Ended			9 Months Ended
	Apr. 22, 2024	Mar. 05, 2024	Mar. 01, 2024	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022
Equity Securities
Common stock, shares authorized				300,000,000			300,000,000		300,000,000
Common stock, shares issued				55,266,435			55,266,435		51,031,000
Common stock, shares outstanding				55,266,435			55,266,435		51,031,000
Preferred stock, shares authorized				10,000,000			10,000,000		10,000,000
Preferred stock, shares issued				0			0
Proceeds from issuance of common stock and warrants in connection with securities purchase agreement, net of issuance costs							$ 13,687,000
Proceeds from issuance of common stock in connection with the At-the-Market offering, net of issuance costs							$ 160,000
Warrant [Member]
Equity Securities
Exercise price per share				$ 3.41			$ 3.41		$ 11.6
Securities Purchase Agreement [Member]
Equity Securities
Gross proceeds		$ 15,000,000	$ 15,000,000
Stock issuance costs							$ 1,300,000
Proceeds from issuance of common stock and warrants in connection with securities purchase agreement, net of issuance costs							13,700,000
Description of purchase agreement			Pursuant to the terms of the Securities Purchase Agreement, until 45 days following the closing of the Offering, the Company agreed not to issue (or enter into any agreement to issue) any shares of common stock or common stock equivalents, subject to certain exceptions. The Company has further agreed not to enter into an agreement involving a variable rate transaction until one year following the closing of the Offering. In addition, the Company’s directors and officers have entered into lock-up agreements with the Company pursuant to which each of them has agreed not to, for a period of 90 days from the closing of the Offering, offer, sell, transfer or otherwise dispose of the Company’s securities, subject to certain exceptions.
Securities Purchase Agreement [Member] | Maxim Group LLC (“Maxim”) [Member]
Equity Securities
Percentage of the aggregate proceeds raised from the sale of securities for cash fee payment to placement agency			7%
Legal expenses, maximum payment under agreement			$ 65,000
Securities Purchase Agreement [Member] | Warrant [Member]
Equity Securities
Exercise price per share			$ 3.8
Warrant term			3 years
Sales Agreement [Member]
Equity Securities
Stock issuance costs							344,000
Gross proceeds							504,000
Proceeds from issuance of common stock in connection with the At-the-Market offering, net of issuance costs							$ 160,000
Sales Agreement [Member] | Jefferies LLC (“Jefferies”) [Member]
Equity Securities
Percentage of the aggregate proceeds raised from the sale of securities for cash fee payment to placement agency	3%
Aggregate offering price	$ 75,000,000
Common Stock [Member]
Equity Securities
Common stock, shares outstanding				55,266,000	55,197,000	54,978,000	55,266,000	51,025	51,031,000	50,799,000	50,789,000	50,736,000
Issuance of common stock and warrants in connection with securities purchase agreement, net of issuance costs (in shares)						3,947,000
Issuance of common stock in connection with At-the-Market offering, net of issuance costs (in shares)				69,000	219,000
Common Stock [Member] | Securities Purchase Agreement [Member]
Equity Securities
Issuance of common stock and warrants in connection with securities purchase agreement, net of issuance costs (in shares)			3,947,368
Common Stock [Member] | Securities Purchase Agreement [Member] | Warrant [Member]
Equity Securities
Number of securities called by warrants			3,947,368
Share price (in dollars per share)			$ 3.8
Common Stock [Member] | Sales Agreement [Member]
Equity Securities
Issuance of common stock in connection with At-the-Market offering, net of issuance costs (in shares)							287,970

A summary of warrant activity f

A summary of warrant activity for the nine months ended September 30, 2024 is presented below (in thousands, except per share and contractual life data). (Details) - Warrant [Member] - $ / shares shares in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Class of Warrant or Right [Line Items]
Number of Shares, Warrants outstanding at beginning balance	9,733
Number of Shares, Issued	3,947
Number of Shares, Exercised
Number of Shares, Forfeited or expired	(3,768)
Number of Shares, Warrants outstanding at ending balance	9,912	9,733
Number of Shares, Warrants exercisable at ending balance	9,912
Weighted Average Exercise Price Per Share, Warrants outstanding at beginning balance	$ 11.6
Weighted Average Exercise Price Per Share, Issued	3.8
Weighted Average Exercise Price Per Share, Exercised
Weighted Average Exercise Price Per Share, Forfeited or expired	24.98
Weighted Average Exercise Price Per Share, Warrants outstanding at ending balance	3.41	$ 11.6
Weighted Average Exercise Price Per Share, Warrants exercisable at ending balance	$ 3.41
Weighted Average Remaining Contractual Life, Warrants outstanding at beginning balance (in Years)	2 years 3 months 10 days	1 year 4 months 24 days
Weighted Average Remaining Contractual Life, Warrants outstanding at ending balance (in Years)	2 years 3 months 10 days	1 year 4 months 24 days
Weighted Average Remaining Contractual Life, Warrants exercisable at ending balance (in Years)	2 years 3 months 10 days

Warrants (Details Narrative)

Warrants (Details Narrative) - USD ($) $ / shares in Units, $ in Millions		3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 01, 2024	Mar. 31, 2024	Sep. 30, 2024	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2023	Jul. 06, 2023
Class of Warrant or Right [Line Items]
Common stock, par value (in dollars per share)								$ 0.0001
Common Stock [Member]
Class of Warrant or Right [Line Items]
Issuance of common stock and warrants in connection with securities purchase agreement, net of issuance costs (in shares)		3,947,000
Securities Purchase Agreement [Member] | Common Stock [Member]
Class of Warrant or Right [Line Items]
Issuance of common stock and warrants in connection with securities purchase agreement, net of issuance costs (in shares)	3,947,368
Common stock, par value (in dollars per share)	$ 0.0001
Warrant [Member]
Class of Warrant or Right [Line Items]
Weighted Average Exercise Price Per Share, Issued			$ 3.8
Exercise price per share			$ 3.41				$ 11.6
Outstanding warrants			9,912,000				9,733,000
Warrant [Member] | Securities Purchase Agreement [Member]
Class of Warrant or Right [Line Items]
Warrant term	3 years
Exercise price per share	$ 3.8
Warrants outstanding, intrinsic value			$ 0
Warrant [Member] | Securities Purchase Agreement [Member] | Common Stock [Member]
Class of Warrant or Right [Line Items]
Number of securities called by warrants	3,947,368
Nano Precision Medical, Inc., Warrant [Member]
Class of Warrant or Right [Line Items]
Weighted Average Exercise Price Per Share, Issued				$ 3.15	$ 3.15	$ 3.15
Exercise price per share			$ 3.15
Number of securities called by each warrant			1
Second Sight Warrant [Member]
Class of Warrant or Right [Line Items]
Exercise price per share			$ 3.75
Outstanding warrants			10,125
Number of securities called by warrants			3,375

A summary of stock option activ

A summary of stock option activity is presented below (in thousands, except per share and contractual life data). (Details) - Share-Based Payment Arrangement, Option [Member] - $ / shares	9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options outstanding at beginning, number of shares (in shares)	6,091,000
Options outstanding at beginning, weighted average exercise price (in dollars per share)	$ 2.6
Granted	1,092,836	1,093,817
Granted, weighted average exercise price (in dollars per share)	$ 1.57
Exercised
Exercised, weighted average exercise price (in dollars per share)
Forfeited or expired	(375,000)
Forfeited or expired, weighted average exercise price (in dollars per share)	$ 1.19
Options outstanding at ending, number of shares (in shares)	6,809,000		6,091,000
Options outstanding at ending, vested and expected to vest (in dollars per share)	$ 2.52		$ 2.6
Options outstanding at ending, vested and expected to vest (in years)	6 years 9 months 18 days		6 years 11 months 15 days
Options exercisable, number of shares (in shares)	4,660,000
Options exercisable, weighted average exercise price (in dollars per share)	$ 2.94
Options exercisable period (in years)	5 years 10 months 13 days

A summary of restricted stock a

A summary of restricted stock activity and related information (in thousands, except per share data): (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Outstanding at beginning, number of shares (in shares)	403,000
Outstanding at beginning, weighted average grant date fair value (in dollars per share)	$ 0.93
Granted	292,500	402,500
Granted	$ 1.69
Vested and released
Vested and released
Forfeited/canceled
Forfeited/canceled
Outstanding at ending, number of shares (in shares)	695,000
Outstanding at ending, weighted average grant date fair value (in dollars per share)	$ 1.25

The following table summarize_2

The following table summarizes total stock-based compensation expense for stock options and RSUs, which is included in the statements of operations (in thousands): (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Allocated share-based compensation expense	$ 472	$ 511	$ 1,208	$ 1,404
Research and Development Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Allocated share-based compensation expense	275	277	757	809
General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Allocated share-based compensation expense	$ 197	$ 234	$ 451	$ 595

Summary of Option and Restricte

Summary of Option and Restricted Stock Units Grant using the Black-Scholes Option-pricing Model and Monte Carlo Simulation model (Details) - $ / shares	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected dividend yield
Expected volatility	100%	100%
Share-Based Payment Arrangement, Option [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Risk-free interest rate	3.79%	3.99%
Expected term	5 years 14 days	4 years
Share-Based Payment Arrangement, Option [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Risk-free interest rate	5.53%	4.45%
Expected term	6 years 29 days	6 years 2 months 12 days
Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
RSUs Granted	292,500	402,500
Valuation date stock price	$ 1.81	$ 0.93
Risk-free interest rate	4.53%	4.13%
Expected dividend yield	0%	0%
Expected volatility	100%	100%
Expected term	4 years	1 year 1 month 6 days

Stock-Based Compensation (Detai

Stock-Based Compensation (Details Narrative)	3 Months Ended		9 Months Ended
	Sep. 30, 2024 USD ($) shares	Sep. 30, 2023 USD ($) $ / shares	Sep. 30, 2024 USD ($) Item $ / shares shares	Sep. 30, 2023 USD ($) Item $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-based compensation expense recognized	$ 472	$ 511	$ 1,208	$ 1,404
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based payment award, award vesting period			4 years
Share-based payment award, award expiration period			10 years
Estimated aggregate intrinsic value of stock options exercisable	10,000		$ 10,000
Unrecognized compensation cost	2,200,000		$ 2,200,000
Weighted average period (in years)			1 year 4 months 24 days
Granted | shares			1,092,836	1,093,817
Granted, weighted average exercise price (in dollars per share) | $ / shares			$ 1.57
Share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average grant date fair value			$ 1,400,000	$ 1,100,000
Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based payment award, award vesting period			4 years	4 years
Granted | shares			292,500	402,500
Share-based payment award, performance vesting criteria, stock price trigger | $ / shares			$ 3.15	$ 3.15
Share-based payment award, performance vesting criteria, threshold consecutive trading days | Item			3	3
Percentage of award shall vest on hurdle achievement date subject to achievement of performance condition			0.33%	0.33%
Percentage of award shall vest first anniversary after hurdle achievement date subject to achievement of performance condition			0.33%	0.33%
Percentage of award shall vest second anniversary after hurdle achievement date subject to achievement of performance condition			0.33%	0.33%
Unrecognized compensation cost	300,000		$ 300,000
Weighted average period (in years)			9 months 18 days
Share-based payment award, award vesting period subsequent to performance period end date			2 years
Share-based payment award, fair value assumptions, expected dividend payments			$ 0
Share-based payment award, award vesting period including subsequent period to performance period end date			6 years
Share-based payment award, forecasted stock price, specified period per year | Item			252
Stock-based compensation expense recognized	126,000,000	$ 0	$ 197,000,000	$ 0
Stock Options (Market Conditions Vesting)
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based payment award, award vesting period				4 years
Share-based payment award, award expiration period				10 years
Share-based payment award, performance vesting criteria, stock price trigger | $ / shares				$ 3.15
Share-based payment award, performance vesting criteria, threshold consecutive trading days | Item				3
Granted | shares				200,000
Share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average grant date fair value				$ 100,000
Common share price | $ / shares		$ 1.09		$ 1.09
Share-based payment award, award vesting period subsequent to performance period end date				2 years
Share-based payment award, fair value assumptions, expected dividend payments				$ 0
Stock-based compensation expense recognized	$ 20,000,000	$ 20,000,000	$ 61,000,000	$ 46,000,000
Equity Incentive Plans [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Issuance shares of common stock | shares	10,033,333		10,033,333
Common stock, shares available for future issuance | shares	2,165,958		2,165,958
Equity Incentive Plans [Member] | Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based payment award, award vesting period			4 years
Share-based payment award, award expiration period			10 years

Net Loss Per Share (Details)

Net Loss Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended						9 Months Ended		15 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Jun. 30, 2024
Earnings Per Share [Abstract]
Net loss	$ (6,041)	$ (5,356)	$ (6,039)	$ (6,782)	$ (6,526)	$ (6,318)	$ (17,436)	$ (19,626)
Weighted average common shares outstanding - basic	55,247			50,837			54,161	50,757
Weighted average common shares outstanding - diluted	55,247			50,837			54,161	50,757
Net loss per common share - basic	$ (0.11)			$ (0.13)			$ (0.32)	$ (0.39)	$ (0.13)
Net loss per common share - diluted	$ (0.11)			$ (0.13)			$ (0.32)	$ (0.39)

Net Loss Per Share (Details 1)

Net Loss Per Share (Details 1) - shares	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	17,416	16,757
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	6,809	6,043
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	695	403
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	9,912	10,311

Right-of-use Assets and Opera_3

Right-of-use Assets and Operating Lease Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Right-of-use Assets And Operating Lease Liabilities
Operating Lease, Right-of-Use Asset	$ 18,383	$ 19,616
Current operating lease liabilities	1,385	1,383
Liabilities, other than long-term debt, noncurrent	$ 18,294	$ 19,313

Right-of-use Assets and Opera_4

Right-of-use Assets and Operating Lease Liabilities (Details 1) $ in Thousands	Sep. 30, 2024 USD ($)
Leases [Abstract]
2024	$ 775
2025	2,914
2026	2,889
2027	2,976
2028	3,065
Thereafter	15,862
Total lease payments	28,481
Imputed interest	(8,802)
Total lease liabilities	$ 19,679
Weighted average discount rate	8.40%
Weighted average remaining lease term	8 years 10 months 24 days

Right-of-use Assets and Opera_5

Right-of-use Assets and Operating Lease Liabilities (Details 2) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Right-of-use Assets And Operating Lease Liabilities
Cash paid for operating lease liabilities	$ 776	$ 375	$ 2,294	$ 1,134

Right-of-use Assets and Opera_6

Right-of-use Assets and Operating Lease Liabilities (Details Narrative)					3 Months Ended		9 Months Ended
	Sep. 30, 2023	Feb. 01, 2023 USD ($)	Jan. 25, 2023	Nov. 21, 2022 ft²	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)
Lease term which are not recorded on the balance sheet							12 months
Description of lease		lease 14,823 square feet of office space at 27200 Tourney Road, Valencia, California 91355.
Description of sub lease terms		The sublease has a term of two years and two months. We also entered into a lease for storage space on January 25, 2023, in the same building at a cost of $6,775 per month for a term of two years and one month.
Operating lease cost					$ 800,000	$ 1,100,000	$ 2,500,000	$ 1,900,000
Operating lease maintenance charges					$ 100,000	$ 400,000	$ 300,000	$ 600,000
Alameda CA [ Member]
Area of building property | ft²				43,645
Lease terminates				The stated term of the lease commenced on June 1, 2023 and terminates on September 30, 2033, ten years and four months. The lease term is based on the non-cancellable period in the lease agreement. There are two options to extend the lease, each for a term of five years; however, the extension options were not included in the measurement of the ROU asset and lease liability since it is not reasonably certain that the Company will exercise such extension options.
Valencia CA [Member]
Net lease agreement description	Payments increase annually from $2,676,311 to $3,596,784, or 124 monthly payments less the first four which are abated, totaling approximately $31.0 million. Vivani is responsible for insurance, property taxes and common area maintenance charges. Vivani deposited $1.3 million to guarantee a letter of credit to secure the lease and this amount is recorded as restricted cash, long-term on the balance sheets as of September 30, 2024 and December 31, 2023.
Lessor [Member]
Lease agreement, effective date		Mar. 01, 2023
Rental payments		$ 22,158
Sublease Storage Space [Member]
Net lease agreement description			The sublease has a term of two years and two months. We also entered into a lease for storage space on January 25, 2023, in the same building at a cost of $6,775 per month for a term of two years and one month.

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) € in Millions				3 Months Ended		9 Months Ended		12 Months Ended
	Dec. 08, 2022	May 19, 2021 USD ($)	May 19, 2021 EUR (€)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)	Apr. 01, 2021 USD ($)
Commitments and Contingencies [Abstract]
Clinical and regulatory expense				$ 3,000	$ 4,000	$ 13,000	$ 119,000
Liquidated damages									$ 1,000,000
Description of contract termination and claims						Pixium indicated that it considered this termination wrongful, rejected the Company’s offers, but retained the $1,000,000 payment. On May 19, 2021, Pixium filed suit in the Paris Commercial Court, and currently claim damages of approximately €5.1 million or about $5.6 million. We believe we have fulfilled our obligations to Pixium with the liquidated damages payment of $1,000,000.
Loss contingency, damages paid, value		$ 1,000,000
Demanded damages, value		$ 5,600,000	€ 5.1
Description of legal settlement	On December 8, 2022, the Company received notice that the Paris Commercial Court has rendered its judgment, including finding that the Company’s termination of the MOU was not valid. In the judgment, the Company was ordered to pay to Pixium the amount of €2,500,000 minus a €947,780 credit for the $1,000,000 already paid for, a net amount payable of approximately €1,552,220. On May 24, 2023, the Company filed an appeal against the judgment from the Paris Commercial Court except in so far as such prior judgment dismissed (i) Pixium’s claim for the Company to pay it a sum of €480,693 relating to the alleged time spent by its teams, (ii) Pixium’s application to order the Company to pay it a sum of €1,500,000 in respect to alleged loss of opportunity and (iii) deducted the sum of $1,000,000 that we already paid Pixium and which Pixium retained converted into euros at the date of the judgment. Thereafter Pixium filed its brief with Paris Court of Appeal and filed a cross-appeal on January 18, 2024. Meanwhile, the Company received notice that the Paris Commercial Court had opened safeguard proceedings against Pixium by judgment dated October 9, 2023, then in its judgment dated November 13, 2023, converted safeguard proceedings into receivership, and in its judgment dated January 31, 2024, converted Pixium’s receivership proceedings to liquidation proceedings, the transfer plan being rejected. As a result, Pixium’s liquidator intervened on behalf of Pixium in the pending proceedings before the Paris Court of Appeal and filed its brief on March 21, 2024. The Company filed its brief in reply with the Paris Court of Appeal on April 17, 2024. Proceedings before the Paris Court of Appeal are pending. In parallel, since the Company has failed to enforce the judgment, Pixium has requested the pre-trial judge to strike out the Company's appeal for failure to enforce the judgment. The hearing took place on June 4, 2024 and on October 23, 2024, the pre-trial judge issued his order, striking out Vivani's appeal for failure to enforce the decision. Within two years, Vivani will have to request that the case be reinstated on the court's docket, providing evidence that the judgment has been fully enforced or, at the very least, that an agreement has been reached. Failing this, the appeal proceedings will lapse.
Charge related to legal settelment								$ 1,675,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - Subsequent Event [Member] - Independent Director, One [Member] - Private Placement [Member]	Nov. 08, 2024 USD ($) $ / shares shares
Subsequent Event [Line Items]
Shares, Issued | shares	3,968,253
Share price | $ / shares	$ 1.26
Period of average closing price of the Company’s common stock on the Nasdaq	5 days
Gross proceeds from the private sale transaction | $	$ 5,000,000